{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T22:52:47Z","timestamp":1777675967609,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T00:00:00Z","timestamp":1493164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16FK0210109H1401"],"award-info":[{"award-number":["16FK0210109H1401"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["16FK0310503H1405"],"award-info":[{"award-number":["16FK0310503H1405"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP26461021"],"award-info":[{"award-number":["JP26461021"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s12328-017-0742-3","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T05:01:58Z","timestamp":1493182918000},"page":"270-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: a case report"],"prefix":"10.1007","volume":"10","author":[{"given":"Ayumu","family":"Yoshikawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsumi","family":"Terashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3891-5113","authenticated-orcid":false,"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soichiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Sarashina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimitsu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susumu","family":"Sogabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Haba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuto","family":"Miyagishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,26]]},"reference":[{"key":"742_CR1","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D","volume":"42","author":"P Cacoub","year":"1999","unstructured":"Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42:2204\u201312.","journal-title":"Arthritis Rheum"},{"key":"742_CR2","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","volume":"10","author":"K Gill","year":"2016","unstructured":"Gill K, Ghazinian H, Manch R, et al. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10:415\u201323.","journal-title":"Hepatol Int"},{"key":"742_CR3","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","volume":"61","author":"F Negro","year":"2014","unstructured":"Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61:S69\u201378.","journal-title":"J Hepatol"},{"key":"742_CR4","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","volume":"62","author":"JM Pawlotsky","year":"2015","unstructured":"Pawlotsky JM, Feld JJ, Zeuzem S, et al. From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol. 2015;62:S87\u201399.","journal-title":"J Hepatol"},{"key":"742_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1601-0825.2010.01670.x","volume":"16","author":"G Lodi","year":"2010","unstructured":"Lodi G, Pellicano R, Carrozzo M. Hepatitis C virus infection and lichen planus: a systematic review with meta-analysis. Oral Dis. 2010;16:601\u201312.","journal-title":"Oral Dis"},{"key":"742_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.cgh.2006.06.010","volume":"5","author":"DR Berk","year":"2007","unstructured":"Berk DR, Mallory SB, Keeffe EB, et al. Dermatologic disorders associated with chronic hepatitis C: effect of interferon therapy. Clin Gastroenterol Hepatol. 2007;5:142\u201351.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"742_CR7","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1159\/000450679","volume":"10","author":"K Misaka","year":"2016","unstructured":"Misaka K, Kishimoto T, Kawahigashi Y, et al. Use of direct-acting antivirals for the treatment of hepatitis C virus-associated oral lichen planus: a case report. Case Rep Gastroenterol. 2016;10:617\u201322.","journal-title":"Case Rep Gastroenterol"},{"key":"742_CR8","doi-asserted-by":"publisher","first-page":"e179","DOI":"10.1038\/ctg.2016.37","volume":"7","author":"Y Nagao","year":"2016","unstructured":"Nagao Y, Kimura K, Kawahigashi Y, et al. Successful treatment of hepatitis C virus-associated oral lichen planus by interferon-free therapy with direct-acting antivirals. Clin Transl Gastroenterol. 2016;7:e179.","journal-title":"Clin Transl Gastroenterol"},{"key":"742_CR9","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/jvh.12312","volume":"21","author":"M Omata","year":"2014","unstructured":"Omata M, Nishiguchi S, Ueno Y, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21:762\u20138.","journal-title":"J Viral Hepat"},{"key":"742_CR10","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/jmv.23777","volume":"86","author":"Y Arase","year":"2014","unstructured":"Arase Y, Kobayashi M, Kawamura Y, et al. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C. J Med Virol. 2014;86:169\u201375.","journal-title":"J Med Virol"},{"key":"742_CR11","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1872-034X.2011.00845.x","volume":"41","author":"Y Arase","year":"2011","unstructured":"Arase Y, Suzuki F, Kawamura Y, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res. 2011;41:946\u201354.","journal-title":"Hepatol Res"},{"key":"742_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1002\/hep.22703","volume":"49","author":"Y Arase","year":"2009","unstructured":"Arase Y, Suzuki F, Suzuki Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology. 2009;49:739\u201344.","journal-title":"Hepatology"},{"key":"742_CR13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/jmv.21691","volume":"82","author":"Y Arase","year":"2010","unstructured":"Arase Y, Suzuki F, Suzuki Y, et al. Virus clearance reduces bone fracture in postmenopausal women with osteoporosis and chronic liver disease caused by hepatitis C virus. J Med Virol. 2010;82:390\u20135.","journal-title":"J Med Virol"},{"key":"742_CR14","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.amjmed.2007.06.022","volume":"120","author":"Y Kawamura","year":"2007","unstructured":"Kawamura Y, Ikeda K, Arase Y, et al. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C. Am J Med. 2007;120:1034\u201341.","journal-title":"Am J Med"},{"key":"742_CR15","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/hep.24724","volume":"55","author":"K Chayama","year":"2012","unstructured":"Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2012;55:742\u20138.","journal-title":"Hepatology"},{"key":"742_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646\u201354.","journal-title":"J Hepatol"},{"key":"742_CR17","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"742_CR18","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655\u201362.","journal-title":"J Hepatol"},{"key":"742_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s00403-016-1667-2","volume":"308","author":"MS Alrashdan","year":"2016","unstructured":"Alrashdan MS, Cirillo N, McCullough M. Oral lichen planus: a literature review and update. Arch Dermatol Res. 2016;308:539\u201351.","journal-title":"Arch Dermatol Res"},{"key":"742_CR20","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1016\/j.jhep.2016.07.039","volume":"65","author":"AJ van der Meer","year":"2016","unstructured":"van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65:S95\u2013108.","journal-title":"J Hepatol"},{"key":"742_CR21","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/hep.27766","volume":"62","author":"HA Innes","year":"2015","unstructured":"Innes HA, McDonald SA, Dillon JF, et al. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. 2015;62:355\u201364.","journal-title":"Hepatology"},{"issue":"3","key":"742_CR22","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/jgh.13589","volume":"32","author":"T Tada","year":"2017","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality, including non-liver-related disease, in patients with progressive hepatitis C virus-related fibrosis. J Gastroenterol Hepatol. 2017;32(3):687\u201394.","journal-title":"J Gastroenterol Hepatol"},{"key":"742_CR23","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/liv.13071","volume":"36","author":"T Tada","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817\u201326.","journal-title":"Liver Int"},{"key":"742_CR24","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1038\/jid.2008.96","volume":"128","author":"J Wenzel","year":"2008","unstructured":"Wenzel J, Tuting T. An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in \u201cinterface dermatitis\u201d. J Invest Dermatol. 2008;128:2392\u2013402.","journal-title":"J Invest Dermatol"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-017-0742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-017-0742-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-017-0742-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T10:03:07Z","timestamp":1589450587000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-017-0742-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,26]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["742"],"URL":"https:\/\/doi.org\/10.1007\/s12328-017-0742-3","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,26]]},"assertion":[{"value":"17 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Professor Naoya Sakamoto received lecture fees from Bristol Myers Squibb and Pharmaceutical K.K; grants and endowments from MSD K.K. and Chugai Pharmaceutical Co., Ltd.; and a research grant from Gilead Sciences, Inc. Dr. Kenichi Morikawa received research grants from Gilead Sciences, Inc. Ayumu Yoshikawa, Katsumi Terashita, Soichiro Matsuda, Takahiro Yamamura, Koichiro Sarashina, Shintaro Nakano, Yoshimitsu Kobayashi, Susumu Sogabe, Kazuhiro Takahashi, Shin Haba, Hisashi Oda, Tatsuro Takahashi, and Takuto Miyagishima declare that they have no conflicts of interest related to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest:"}},{"value":"All procedures were in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Rights:"}},{"value":"Informed consent for inclusion in this report was obtained from the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent:"}}]}}